Magenta Therapeutics, Inc.’ $64.8 Million Follow-On Offering


Davis Polk advised the joint book-running managers and representatives of the underwriters in connection with the $64.8 million follow-on offering of common stock of Magenta Therapeutics, Inc., which includes the full exercise of the underwriters’ option to purchase additional common stock.

The common stock is listed on the Nasdaq Global Market under the symbol “MGTA.”

J.P. Morgan, Goldman Sachs & Co. LLC, Cowen and Wedbush PacGrow acted as joint book running managers for the offering.

Headquartered in Cambridge, Massachusetts, Magenta Therapeutics is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune diseases, blood cancers and genetic diseases.

The Davis Polk capital markets team included partner Deanna L. Kirkpatrick (Picture) and associates Jennifer Ying Lan and Amy Mao. Partner David R. Bauer and associate Jesse L. Hallock provided intellectual property and technology advice. The tax team included partner Michael Mollerus and associate Joseph M. Gerstel. Counsel Marcie A. Goldstein provided FINRA advice.

Involved fees earner: David Bauer – Davis Polk & Wardwell; Joseph Gerstel – Davis Polk & Wardwell; Marcie Goldstein – Davis Polk & Wardwell; Jesse Hallock – Davis Polk & Wardwell; Deanna Kirkpatrick – Davis Polk & Wardwell; Amy Mao – Davis Polk & Wardwell; Michael Mollerus – Davis Polk & Wardwell; Jennifer Ying Lan – Davis Polk & Wardwell;

Law Firms: Davis Polk & Wardwell;

Clients: Cowen and Company; Goldman Sachs & Co.; J.P. Morgan Securities LLC; Wedbush PacGrow;

Print Friendly, PDF & Email

Author: Ambrogio Visconti